Loading clinical trials...
Loading clinical trials...
Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse Who Are Eligible for High Dose Treatment Followed by Autologous Peripheral Blood Stem Cell Transplantation (ASCT)
Conditions
Interventions
DHAP
Brentuximab Vedotin
+1 more
Locations
13
Denmark
Rigshospitalet
Copenhagen, Denmark
Centre Hospitalier Universitaire
Lille, France
Hospices Civils de Lyon
Lyon, France
Centre Hospitalier et Universitaire
Nantes, France
Hôpital Saint Louis
Paris, France
Institut Gustave Roussy
Paris, France
Start Date
May 1, 2014
Primary Completion Date
November 1, 2018
Completion Date
May 1, 2020
Last Updated
March 13, 2018
NCT05053971
NCT05529069
NCT05039801
NCT06189391
NCT07350863
NCT04973605
Lead Sponsor
Marjolein Spiering
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions